Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT06591221
Active, not recruiting Not applicable

The Effectiveness of Chuna Maintenance Therapy for Chronic Bothersome Neck Pain

NCT06591221 · tracked via the Priya Life Science South Korea tracker
Phase
Not applicable
Started
2024-07-07
Last updated
2026-05-28

Condition(s) studied

Neck PainChronic Pain

Investigational drug(s) / intervention(s)

Chuna Maintenance Therapy

Chuna Maintenance Therapy: it is conducted every two weeks for a total of 20 weeks for individuals. The technique follows the guidelines of the Society of Chuna Manual Medicine and is based on Chuna Medicine (2.5th edition), which is utilized as a textbook in Korean Medicine colleges. The treatment is selectively administered based on the clinical judgment of the practitioner.

Study summary

This study is a pragmatic randomized controlled study that assessed 250 subjects complaining of chronic bothersome neck pain with mild discomfort in a 1:1 ratio: chuna maintenance therapy group (125 subjects, 1 time/2 weeks, total 20 weeks) and lifestyle management \& self-exercise group (125 subjects, exercise method education 1 time/4 weeks, total 20 weeks).

Eligibility

Sex
ALL
Min age
19 Years
Max age
70 Years
Healthy volunteers
No
* Inclusion Criteria: 1. Aged 19 or older but under 70. 2. Neck pain with pain duration of 12 months or longer 3. NRS of neck pain over the past month is 2 or more but less than 4 4. Patients who have agreed to trial participation and provided written informed consent * Exclusion Criteria: 1. Patients diagnosed with serious pathology(s) which may cause neck pain (e.g. spinal metastasis of tumor(s), acute fracture, spinal dislocation) 2. Patients with progressive neurologic deficit or severe neurologic symptoms such as spinal cord injury 3. Patients whose pain is due to soft tissue disease not the spine (e.g. tumors, fibromyalgia, rheumatoid arthritis, gout) 4. Patients with other chronic disease(s) which may interfere with treatment effect, safety, or interpretation of outcome (e.g. stroke and myocardial infarction, kidney disease, diabetic neuropathy, dementia, epilepsy) 5. Patients currently taking steroids, immunosuppressants, medicine for mental illness or other medication(s) that may interfere with study results 6. Pregnant patients or patients with plans of pregnancy or lactating patients 7. Patients within 3 months after cervical surgery 8. Patients with experience of participating in another clinical study within 1 month or plan to participate in another clinical study during the study participation and follow-up period within 6 months from the participation date 9. Patients having difficult to completing the written informed consent 10. Patients who are deemed unsuitable by the researchers

Primary outcome measure(s)

Trial sites (7)

FacilityCityRegionStatus
Bucheon Jaseng Hospital of Korean Medicine Bucheon-si South Korea
Daejeon Jaseng Hospital of Korean Medicine Daejeon South Korea
Haeundae Jaseng Hospital of Korean Medicine Haeundae South Korea
College of Korean Medicine, Kyung Hee University Seoul South Korea
Department of Acupuncture & Moxibustion Medicine, College of Korean Medicine, Kyung Hee University Seoul South Korea
Jaseng Hospital of Korean Medicine Seoul South Korea
School of Korean Medicine, Pusan National University Yangsan South Korea

More Jaseng Medical Foundation trials in South Korea

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06591221 on ClinicalTrials.gov ↗ ← All trials in South Korea